Learn about our new test breakthough

Breakthrough, Standalone Liquid Biopsy Urine Test for Prostate Cancer

miR Scientific’s Sentinel™ Test is the only standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and monitors prostate cancer at the molecular level with 95% specificity and sensitivity.

Learn More

99%

Survival rate with
early-stage diagnosis

39%

Only 39% of the eligible market
in the US is being screened.

cancer free couplecancer free man

Actionable Answers To The
Most Important Questions

The miR Scientific Disease Management Platform® is transforming cancer management by delivering actionable and accurate results to physicians and patients from a single urine sample, answering the three most important questions:

Is cancer present? How severe is it? What’s next?

Get Your Answers

1in9

1 in 9 men will have prostate cancer in their lifetime

1.3M

New prostate cancer cases are diagnosed globally every year

1
1 in 7 men will have prostate cancer in their lifetime.
2
Only 50–60% of the 30 million age-eligible men receive timely prostate cancer screening
3
Late-stage prostate cancer diagnosis has only a 28% five-year survival rate
4
Men with early-stage diagnoses have a nearly 100% survival rate and avoid the high costs of aggressive late-stage treatments.

The miR Scientific Sentinel Test Provides One Of Four Results:

No Cancer

Our technology identifies molecular evidence of malignancies from the entire prostate gland, even in early onset of the disease, so if the test shows that cancer is not present, patients and physicians can confidently conclude that no cancer is present at the time of diagnosis.  No means No.

Yes Cancer/Low Risk

An overwhelming majority of prostate cancer patients have an indolent, or clinically insignificant localized cancer that does not require a definitive treatment.  For patients with low risk classifications, a physician may recommend a follow up under an active surveillance protocol, which for patients simply entails providing more urine samples periodically to ensure the disease has not progressed.

Yes Cancer/Intermediate Risk

Approximately GG2; Depending on the risk tolerance of patients and physicians, they may decide on monitoring the disease for progression non-invasively under an active surveillance protocol or elect to undergo a definitive treatment.

Yes Cancer/High Risk

Patients whose molecular signature indicates the presence of high grade disease typically would undergo interventional definitive treatment, the specifics of which will be determined by the specialist care provider.
Clear YES/NO answer to the question if prostate cancer is present.  
Our technology identifies molecular evidence of the malignancies from the entire prostate gland, even in early onset of the disease.  Yes means Yes and No means NO.

Making Healthcare History

miR is healthcare’s first truly standalone urine test that diagnoses and classifies prostate cancers with 95% specificity and sensitivity—no rectal exam, blood test, biopsy, or strict urine requirements.

Any urine, any time gives you the most complete prostate cancer surveillance and clinical decision-making support across the continuum of cancer care.

Learn more about the breakthrough accuracy of our sncRNA testing techniques and proprietary scoring algorithm.

Get Your Answers

Current Failing Standard of Care

Invasive, expensive and innacurate with 44% sensistivity.

Primary Care Visit

Urologist Visit

2 Digital Rectal Exams

2 PSA Blood Tests

1 or More Prostate Biopsies

The New Standard

Easily Administered, Pain-Free & Non-invasive

1 Urine Sample

Follow Up Care if Necessary

95% Specificity and Sensitivity

Easily Administered

Non-Invasive

Current Failing Standard of Care

Primary Care Visit

Urologist Visit

2 Digital Rectal Exams

2 PSA Blood Tests

1 or More Prostate Biopsies

Invasive Expensive & Inaccurate

44% Sensitivity

1 Urine Sample

Follow Up Care if Necessary

95% Specificity and Sensitivity

Easily Administered

Pain-Free

Non-Invasive

miR Solution

A Novel, Proprietary Test with Breakthrough Results

Our molecular diagnostic capabilities approach cancer detection, classification, and monitoring through a new lens with advanced sncRNA interrogation techniques, a proprietary scoring algorithm, and innovative clinical decision support tools.

Greatly reduce the stress and uncertainty surrounding prostate cancer screening with a straightforward and effective urine test that delivers accurate results.

Learn More

Uniquely miR

Accurate

Accelerate the right diagnosis and treatment for individual cancer management with accurate diagnosis, classification, and monitoring.

Non-Invasive

Help patients avoid the invasive, inaccurate, and painful diagnostic procedures that are the current standard of care. miR delivers results with zero contact.

Stand Alone

Broaden access to life-saving cancer screening with a completely standalone urine test that diagnoses and classifies prostate cancer with no additional testing requirements.

Validated

The miR disease management platform is peer-reviewed and validated for the screening and classification of prostate cancer.

Efficient

Rapid turnaround of reliable information guides treatment decisions and enables true cost-effectiveness in prostate cancer screening and management.

Scalable

Unlike biopsies, MRIs, and other current options, the miR platform is high-throughput, easily administered, and cost-effective for large volumes of patients.

Why It Matters

Providers

Leverage the most accurate prostate cancer decision-making platform to identify and rapidly treat patients with the greatest need.

Patients

Experience a non-invasive, accurate, accessible prostate cancer test that delivers clear results to you and your doctor with a single urine specimen.

Employers

Keep your employees healthy and productive while reducing excessive urologic cancer screening and treatment costs.

It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management.  Unlike other cancers, most prostate cancers are indolent and are unlikely to ever need treatment, and only a relatively small number of prostate cancer patients have aggressive disease that requires intervention.  The challenge lies in effectively differentiating between the two, quickly, but until now, no effective, accurate and non-invasive tests have been developed for the early detection and grade classification of prostate cancer.

Everyone Benefits

Our non-invasive, pain-free prostate cancer diagnostic testing and monitoring platform helps physicians, patients, and payors realize true cost-effectiveness and efficiency in prostate cancer screening and management for the first time.

Providers

Leverage the most accurate prostate cancer decision-making platform to identify and rapidly treat patients with the greatest need.

Patients

Experience a non-invasive, accurate, accessible prostate cancer test that delivers clear results to you and your doctor with a single urine specimen.

Employers

Keep your employees healthy and productive while reducing excessive urologic cancer screening and treatment costs.

Today’s Standard Of Care Is Ineffective

The current standard of care relies on PSA (Prostate Specific Antigen) and Digital Rectal Exams (DRE) to trigger core needle biopsies for the detection and diagnosis of prostate cancer.

Learn More

Leading Cause
of Cancer

Prostate Cancer is the leading cause of cancer and 2nd leading cause of cancer death in US men

New Cases
Globally

1.3M new prostate cancer cases are diagnosed globally every year

Affects
1 in 9 Men

1 in 9 men will have prostate cancer in their lifetime

When it comes to cancer, do you want more questions or more answers?

Avoid the inaccurate blood tests and painful biopsies and get complete cancer diagnosis and classification information from one urine sample.

Contact miR